



COVID-19 Vaccine Development and Vaccination

Collection Editors:

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, University of Georgia,
Athens, GA 30602, USA

Dr. Scott Anthony

National Institute of Allergy and
Infectious Diseases (NIAID),
Frederick, MD, USA

Message from the Collection Editors

COVID-19 vaccines significantly reduce the risk of illness or death from the disease. Each vaccine stimulates the immune system to produce antibodies that combat the virus. The vaccines utilize a harmless version of a structure resembling the spike protein found on the surface of the virus. In the United States, the following COVID-19 vaccines are available:

- Pfizer-BioNTech COVID-19 vaccine (2024–2025 formula) for individuals aged 6 months and older.
- Moderna COVID-19 vaccine (2024–2025 formula) for individuals aged 6 months and older.
- Novavax COVID-19 vaccine (2024–2025 formula) for individuals aged 12 years and older.

These vaccines have received emergency use authorization or approval from the U.S. Food and Drug Administration (FDA). This collection on “COVID-19 Vaccine Development and Vaccination” will showcase recent efforts to develop, test, and administer vaccines against SARS-CoV-2.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)